News | September 05, 2025
FDA completes inspection at Biocon Biologics' facility in Bengaluru
The U.S. FDA issued a Form 483 with five observations
The U.S. FDA issued a Form 483 with five observations
The medicine was well tolerated, with no unexpected safety issue
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
These orders are from international government tenders in South Africa, Tanzania, and Kenya, as well as from international agencies WHO/UNFPA, NGOs like MSI and PSI
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
Subscribe To Our Newsletter & Stay Updated
